Direct Factory Supply with Complete cGMP Documentation and High Purity Assurance
Selank is a synthetic regulatory heptapeptide derived from the naturally occurring human tetrapeptide Tuftsin (Thr-Lys-Pro-Arg). By extending the native sequence at the C-terminus with a Proline-Glycine-Proline (PGP) tripeptide motif, Russian neuroscientists created a highly stable, enzymatically resistant analog known structurally as Thr-Lys-Pro-Arg-Pro-Gly-Pro Acetate. In global pharmaceutical B2B markets, wholesale Selank 5mg vials represent a critical standard unit for research organizations, biotech developers, and clinical formulation labs looking for standardized dosing profiles.
Key Analytical Specification: Standard enterprise Selank 5mg finished vials require pure lyophilized cake appearance, minimum 99.0% purity verified by RP-HPLC, single impurity threshold < 0.5%, and trifluoroacetic acid (TFA) residual content below 1.0% (preferably counter-ion exchanged to Acetate salt form).
| Parameter | Technical Specification & Standard |
|---|---|
| Chemical Name | Selank Acetate (Thr-Lys-Pro-Arg-Pro-Gly-Pro) |
| CAS Registry Number | 129954-34-3 (Free Base: 116854-19-4) |
| Molecular Formula | C33H57N11O9 (Free Peptide Base) |
| Molecular Weight | 751.9 g/mol |
| Sequence | H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH |
| Standard Unit Dosage | 5mg / Vial (Lyophilized Powder, Sealed under Nitrogen) |
| Formulation Matrix | Mannitol / Glycine Excipient Matrix (Optional for OEM) |
| Biological Class | Synthetic Heptapeptide / Nootropic & Immunomodulatory Regulatory Peptide |
Market Drivers, Supply Chain Logistics, and Bulk OEM Manufacturing Trends
The global demand for synthetic regulatory peptides like Selank and Semax has experienced exponential growth. Commercial contract development and manufacturing organizations (CDMOs) report increased inquiries for batch sizes ranging from 1,000 to 50,000 vials of 5mg Selank, driven by clinical trials and academic investigations into CNS modulation.
B2B buyers in North America, the European Union, and LATAM are shifting away from unverified suppliers toward fully audited API manufacturers. Compliance with ISO 9001:2015, WHO-GMP, and cleanroom air classifications (Class 100 / ISO 5 for lyophilizate filling) has become mandatory for enterprise procurement.
Selank in lyophilized form exhibits solid thermal stability at ambient temperatures for short durations, but long-term enterprise storage protocol dictates strict maintaining of -20°C conditions. Intact cold-chain logistics (2-8°C shipping with dry ice or phase-change packs) prevent peptide degradation via deamidation or peptide cleavage.
Enterprise procurement strategies vary significantly across geographic territories:
From Amino Acid Coupling to Lyophilization: Technical Execution Whitepaper
Industrial scale manufacturing of Selank 5mg employs Fmoc-based Solid-Phase Peptide Synthesis (Fmoc-SPPS) on automated multi-liter glass reactors. The C-terminal Proline residue is immobilized on a suitable resin matrix, typically CTC (2-Chlorotrityl chloride) resin, to minimize racemization and diketopiperazine formation during initial coupling steps.
Sequential coupling reactions utilize high-efficiency activators such as HBTU/HOBt or HATU in N,N-Dimethylformamide (DMF) solvent, with Diisopropylethylamine (DIPEA) as the organic base. Deprotection of N-alpha-Fmoc groups is executed using 20% Piperidine in DMF.
Once the full heptapeptide sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is assembled, global cleavage from the resin and simultaneous removal of side-chain protecting groups (e.g., Lys(Boc), Thr(tBu), Arg(Pbf)) is accomplished using a TFA cleavage cocktail:
Standard Cleavage Cocktail Ratio: Trifluoroacetic Acid (95%) : Triisopropylsilane (TIS, 2.5%) : Water (2.5%). Reaction time: 2.5 hours at 20°C under nitrogen atmosphere.
Because TFA salts can cause cytotoxic responses in research models, commercial enterprise standards require counter-ion conversion. The crude TFA salt is converted to Selank Acetate using ion-exchange resin columns or preparative RP-HPLC gradient elution with ammonium acetate buffer solutions, reducing residual TFA to < 0.5%.
Purification is performed using Preparative Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) equipped with C18 silica columns (100Å or 300Å pore size, 10µm particle size). A binary gradient system consisting of Phase A (0.1% Acetic Acid in H2O) and Phase B (100% Acetonitrile) achieves target purities exceeding 99.0%.
Monitors chemical purity, retention time, and individual impurity peaks. Threshold for single maximal impurity is strictly kept below <0.5%.
ESI-MS confirms the exact monoisotopic mass of Selank base (751.4 M+H+), proving sequence identity without fragmentation errors.
LAL (Limulus Amebocyte Lysate) assay guarantees bacterial endotoxin content remains strictly < 0.05 EU/mg for enterprise batches.
Emerging Manufacturing Methodologies, Delivery Systems & Green Chemistry Initiatives
As the pharmaceutical industry moves toward sustainable and cost-effective peptide production, several key technological transformations are shaping the future manufacturing landscape of Selank 5mg:
| Innovation Pillar | Current Industry Benchmark | Next-Generation Development Horizon |
|---|---|---|
| Synthesis Methodology | Batch Fmoc-SPPS with organic solvents (DMF/NMP) | Continuous Flow Peptide Synthesis (CFPS) & Liquid-Phase Hybrid Synthesis (LPPS) for mass scaling. |
| Green Chemistry | Hazardous coupling reagents & high solvent consumption | Water-soluble coupling reagents, replacement of DMF with non-toxic solvents (e.g., Cyrene, TAME). |
| Formulation Technology | Standard lyophilized powder for reconstitution | Intranasal nano-emulsions, liposomal encapsulation, and sustained-release biodegradable microspheres. |
| Process Analytical Tech (PAT) | Post-batch HPLC/MS testing | Real-time inline UV-Vis spectrophotometry and NIR monitoring during automated synthesis. |
Comprehensive API Procurement, Custom Synthesis, and Laboratory Setup Options
Gentolex Group offers holistic, integrated services designed to eliminate complexity in global peptide supply chains. By establishing direct contracts with raw material synthesis facilities and commercial packaging plants, we provide an end-to-end operational framework for global biotech firms.
Supplying raw peptide APIs and specialized custom sequence synthesis from milligram research quantities up to multi-kilogram commercial production batches.
Finished Dosage Form (FDF) licensing services, enabling international pharmaceutical brands to rapidly launch fully compliant commercial products in local markets.
Expert advisory on regulatory dossier submission (DMF), analytical method validation, peptide stability testing, and freeze-drying optimization.
Engineering and setup solutions for peptide synthesis suites, high-capacity lyophilizers, cleanroom sterile liquid lines, and analytical laboratories.
For clients seeking to simplify vendor management, we offer consolidated procurement across complex raw materials, protecting your supply chain from bottlenecks.
Direct service coverage in over 10 countries with dedicated operational hubs established in key global nodes, including Mexico and South Africa.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
With an overall factory construction area of 250,000 square meters operating under international standards, we offer flexible, scalable, and cost-effective chemical and pharmaceutical solutions. Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates (COA, MSDS, HPLC, MS, DMF) are supported to customers worldwide.
Deep-Dive Articles on Neuro-Active Peptides & Mitochondrial Target Compounds
Direct Expert Clarification for Quality Assurance Managers and Sourcing Executives
Explore Extended Product Line Options Available for Bulk Procurement
